Diane C. Young is VP at Celldex Therapeutics, Inc. (CLDX). They have made 6 open-market trades across 2 companies since 2016, most recently 2024-06-11.
CIK 0001648010
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2020, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLDX | SELL | 2024-06-07 | 2024-06-11 | $35.26 | $1.6M | -2.2% | +3.9% | +14.3% |
| CLDX | SELL | 2022-08-17 | 2022-08-19 | $37.30 | $709K | -6.6% | -9.4% | +5.3% |
| CLDX | SELL | 2021-11-12 | 2021-11-16 | $42.94 | $198K | -12.7% | -18.9% | -28.7% |
| CLDX | BUY | 2020-06-11 | 2020-06-12 | $4.73 | $10K | +66.1% | +51.3% | +58.9% |
| GTXI | SELL | 2018-07-16 | 2018-07-17 | $14.70 | $30K | +13.9% | +20.1% | -89.5% |
| GTXI | SELL | 2016-10-28 | 2017-02-28 | $7.70 | $4K | +6.6% | +4.7% | -35.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.